Setting Realistic Expectations: What GLP-1 Will (and Won’t) Do

Introduction

The headlines around semaglutide and tirzepatide focus on the average. STEP 1 showed 14.9% mean weight loss at 68 weeks. SURMOUNT-1 showed 20.9%. The pictures circulating are usually of people at the upper end of the response curve, with dramatic transformations.

The reality for most patients is more varied. About a third lose less than the trial average. About a quarter lose more. A small percentage barely respond at all. And the weight loss number doesn’t capture everything that changes, both for better and for worse.

This article tries to set realistic expectations across what the drugs do, what they don’t, how long it takes, and what life looks like on them.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Much Weight Will I Actually Lose?

The honest answer is somewhere between 5% and 25%, with most people landing in the 10-20% range. The trial averages are useful anchors but they hide individual variation.

Quick Answer: STEP 1 (Wilding et al. 2021 NEJM) showed 14.9% mean weight loss on semaglutide 2.4 mg at 68 weeks, with a range of about -25% to 0

For semaglutide 2.4 mg, the STEP 1 trial published in NEJM by Wilding et al. 2021 showed mean weight loss of 14.9% at 68 weeks compared with 2.4% on placebo. About 32% of patients lost 20% or more. About 14% lost less than 5%.

For tirzepatide 15 mg, the SURMOUNT-1 trial by Jastreboff et al. 2022 in NEJM showed mean weight loss of 20.9% at 72 weeks. About 36% lost 25% or more. About 9% lost less than 5%.

Real-world data from telehealth and clinic settings tends to show slightly lower averages, often 10-15%, because adherence is lower outside of trials and dosing may not always reach the maximum.

What Predicts How Much Weight Someone Will Lose?

Several factors. Starting BMI affects absolute weight loss but not percentage weight loss. People at BMI 40 lose more pounds than people at BMI 30, but roughly the same percentage of body weight.

Female sex is associated with slightly larger percentage losses in most trials. Type 2 diabetes is associated with smaller losses, around 4-6% less than non-diabetic patients on the same dose.

Early response predicts later response. Patients who lose 5% in the first 16 weeks tend to keep losing. Those who lose less than 5% in that window are unlikely to reach trial averages.

Genetics probably matter too, though we don’t yet have validated genetic predictors. Adherence, including not skipping doses and reaching the maximum tolerated dose, is one of the strongest predictors of real-world response.

How Long Does It Take to See Results?

The first few pounds usually come off within the first month, often before reaching therapeutic doses. This is mostly water and reduced food volume from slowed gastric emptying.

Real weight loss accelerates around weeks 8-16, once you’ve titrated up to higher doses. Most patients lose 1-2 pounds per week during this phase.

The pace slows after about 6 months as you approach your new set point. By month 12-15, most patients have hit their plateau and weight stabilizes. Beyond that, additional loss is possible but slow.

The STEP 5 trial published in Nature Medicine in 2022 by Garvey and colleagues followed patients out to 104 weeks and showed weight loss largely plateaued by week 60 and was maintained through the rest of the trial.

What Does GLP-1 Not Do?

It doesn’t reshape your body composition independently of weight loss. About 25-40% of the weight lost on GLP-1 drugs is lean mass, including muscle. This is a higher proportion of lean loss than bariatric surgery, which loses around 20% lean. Resistance training and adequate protein intake (about 1.0-1.6 g/kg of goal body weight) can blunt this, but it’s a real concern.

It doesn’t fix loose skin. Significant rapid weight loss often leaves loose skin, especially in the abdomen, arms, and chest. Skin elasticity depends on age, genetics, and how long you carried the weight. Skin tightening is gradual and incomplete, and surgical removal is sometimes considered after weight stabilizes.

It doesn’t cure obesity. When you stop the drug, weight comes back for most people. The STEP 4 trial by Rubino et al. 2021 in JAMA showed about two-thirds of weight regained within a year of stopping semaglutide. Obesity is a chronic disease and pharmacological treatment is generally long-term.

It doesn’t replace exercise or nutrition. Cardiovascular fitness, strength, bone density, and metabolic flexibility don’t improve from weight loss alone. They require exercise.

Will I Keep Losing Weight If I Stay on the Drug?

Not indefinitely. Most patients reach a plateau between months 12 and 18 where weight loss stops despite continuing the drug. This is normal. Your body has reached a new homeostatic set point.

If you’re not at your goal weight at the plateau, options include dose adjustment (some patients respond to going from 2.4 mg semaglutide to 15 mg tirzepatide, or vice versa), adding behavioral interventions, or accepting the new baseline.

A small minority of patients keep losing slowly over years 2-3 of treatment. The Garvey 2022 STEP 5 trial showed about 2-3% additional loss in year 2 beyond what was achieved in year 1.

The goal of long-term treatment is usually maintenance rather than continued loss after the initial plateau.

What About Non-weight Benefits?

Significant, and often underappreciated. The SELECT trial by Lincoff et al. 2023 NEJM showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in non-diabetic patients with obesity over about 40 months on semaglutide. This was independent of how much weight patients lost.

The FLOW trial by Perkovic et al. 2024 NEJM showed a 24% reduction in major kidney events or cardiovascular death in diabetic kidney disease.

STEP-HFpEF showed improved symptoms and exercise capacity in heart failure with preserved ejection fraction.

SURMOUNT-OSA led to FDA approval of tirzepatide for obstructive sleep apnea in December 2024 based on substantial improvements in apnea-hypopnea index.

These benefits are real, mostly independent of weight loss magnitude, and persist as long as the drug is taken.

Key Takeaway: Roughly 10-15% of patients are “non-responders” who lose less than 5% on either drug

What Are Realistic Side Effect Expectations?

About 80% of patients experience some GI side effects, especially during dose titration. Nausea is most common, occurring in roughly 40-45% of patients in the STEP 1 trial. Vomiting, diarrhea, and constipation are each in the 15-25% range.

Most side effects are mild to moderate and improve over time. About 5-10% of patients discontinue due to side effects.

Less common but more serious risks include pancreatitis (less than 0.5% per year), gallbladder events (around 2.5% in STEP 1), and rare cases of bowel obstruction or gastroparesis. The FDA added warnings for ileus and aspiration risk during anesthesia.

The boxed warning for medullary thyroid cancer in rodents has not been confirmed in humans, but family history of MTC or MEN 2 is a contraindication.

How Much Will I Have to Change My Eating to Make This Work?

Less than with diet alone, but the drug works best paired with reasonable habits. The mechanism is appetite suppression and reduced food noise, so eating becomes more matched hunger by default.

Practical changes most patients need to make include prioritizing protein at meals to preserve muscle (aim for 25-40 grams at the main meal), staying hydrated since reduced appetite often reduces water intake, and avoiding heavy fatty meals that worsen nausea.

You don’t need to count calories or follow a specific diet for the drug to work. Most patients naturally fall into a moderate-protein, moderate-vegetable pattern because that’s what their reduced appetite tolerates.

What If I’m a Non-responder?

Defined as less than 5% loss at 16 weeks on a therapeutic dose, this affects about 10-15% of patients on semaglutide and 5-10% on tirzepatide. Options include switching between the two drugs (some patients respond well to one but not the other), maximizing the dose, adding behavioral support, or recognizing that pharmacological treatment may not be the right tool for you.

Bariatric surgery remains the gold standard for treatment-resistant obesity, with weight loss of 25-30% sustained at 10 years in most patients.

How Does TrimRx Structure Expectations During Treatment?

The personalized treatment plan starts with an assessment of baseline health, goals, and motivation. Initial expectations are typically set around 10-15% weight loss over the first year, with cardiovascular and metabolic benefits accruing in parallel. The free assessment quiz collects the information needed to set those expectations realistically.

Follow-up assessments at 4, 8, 12, and 24 weeks track progress against expected response curves. Patients who aren’t responding as expected can have dose adjustments, drug switches, or referrals for additional support.

The model is built around long-term engagement rather than rapid loss followed by drop-off, which the trial data suggests is the realistic shape of successful obesity treatment.

What About the Psychological Adjustment to Weight Loss?

Often underdiscussed but real. Significant weight loss changes how you see yourself, how others see you, and how you interact with the world. Some changes are welcome. Others are disorienting.

Body image lag is common, where you continue to see yourself as your previous size despite weight loss. Some patients find this resolves over time. Others find professional support helpful.

Social dynamics shift, including increased attention from strangers, changes in established relationships, and adjustments in family dynamics around food and meals.

Identity may need rebuilding. People who’d identified as “the fat friend” or built their self-concept around weight struggles have to find new internal narratives. This isn’t pathological, but it’s real work.

Bottom line: About two-thirds of weight is regained within a year of stopping, per STEP 4 (Rubino et al. 2021 JAMA)

FAQ

How Much Will I Lose in the First Month?

Usually 3-8 pounds, much of it from reduced food volume and water. This is not predictive of long-term loss.

Can I Expect to Look Like the People in the Before-and-after Photos?

Some patients do. Most don’t. Photos circulating online are typically from the upper end of the response curve. Set expectations based on the average (around 15-20%) rather than the extremes.

Will I Lose Weight in Specific Areas Like Belly Fat?

GLP-1 drugs preferentially reduce visceral fat, the metabolically active fat around organs. Belly fat usually shrinks faster than subcutaneous fat elsewhere. But you can’t fully target where fat comes off.

What If I Gain Weight on the Drug?

Uncommon but possible. Causes include insufficient dose, missing injections, severe stress or new medications affecting appetite, or being a non-responder. Talk to your prescriber about dose or drug changes.

How Will I Know What My Realistic Target Weight Is?

The medical convention is to aim for 5-15% loss as a starting goal, since most cardiometabolic benefits accrue in that range. Most patients exceed this on GLP-1 drugs. A reasonable target with TrimRx is to follow the curve of your response over the first 6-9 months and see where your body settles.

Will I Have to Stay on This Forever?

Most likely yes, if you want to keep the weight off. Some patients try maintenance with lower doses or longer intervals between injections. A minority maintain off the drug with intensive behavior change. Plan as if it’s a long-term medication.

How Is TrimRx Different From Getting Semaglutide From My Doctor?

TrimRx is a telehealth platform offering compounded semaglutide and tirzepatide. The drugs are prescribed through licensed US providers after a personalized assessment quiz. Cost is generally lower than brand-name versions, and the model is built around remote care and medication delivery.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.